Syncromune, Inc.

Syncromune, Inc.

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform therapy that combines a multi-target biologic drug and partial tumor oncolysis. SYNC-T is designed to create a personalized in situ vaccine and target multiple mechanisms of cancer, promoting immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.

Breast Cancer, Genitourinary Cancer, Lung Cancer, Metastatic Disease, Immunotherapy

Yes